The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.

Berry ButtonSarah CroessmannDavid ChuD Marc RosenDaniel J ZabranskyW Brian DaltonKaren CraveroKelly Kyker-SnowmanIan WatersSwathi KarthikeyanEric S ChristensonJosh DonaldsonTasha HunterLauren DennisonCody RaminBetty MayRichard RodenDana PetryDeborah K ArmstrongKala VisvanathanBen Ho Park

Published in: Breast cancer research and treatment (2018)

This study suggests that the ER S118P variant does not affect risk for breast cancer or hormone therapy resistance. Germline screening and modification of treatments for patients harboring this variant are likely not warranted.

Keyphrases

estrogen receptor
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
stem cells
dna repair
young adults
patient reported
dna damage
breast cancer cells
breast cancer risk